ImmunoPrecise (IPA) and Eurofins Discovery have joined forces. Together—we accelerate antibody discovery breakthrough, expand access to experts on a global scale and provide service excellence from end-to-end—better.
ImmunoPrecise (IPA) is collaborating with Eurofins Discovery to enhance our services to you. This collaboration will strengthen our capacity as a single-source provider, and as a leader in full-spectrum antibody services. Eurofins Discovery, a division of Eurofins Scientific, is a leading international group of laboratories providing a unique range of analytical testing services.
Meet the team committed to conquering your toughest antibody target challenge.
Together, IPA and Eurofins Discovery are uniquely equipped to address the complex challenges of antibody discovery projects. With a veritable think-tank of the industry’s leading experts, we explore beyond the status quo to deliver breakthrough preclinical antibody candidates and give you the edge with single-source services.
ImmunoPrecise is an innovation-driven technology platform company with a distinctive end-to-end service model, designed to reduce time and risk with custom applications. We support our business partners in the quest to discover and develop novel antibodies against a broad range of classes of disease targets in one stop, with:
The IPA mission is to provide capacity, breadth of offerings, and unique platforms that accelerate assay development, screening cascades, drug candidate validation and new biotherapeutic concepts. Our partnership with Eurofins Discovery adds:
When you entrust your target challenge to us, you set excellence in motion. The ImmunoPrecise and Eurofins partnership brings multidisciplinary experts with vast experience, precision processes and the will to win together—to navigate your project and multiple target types through all tests and phases.
Learn more or get started with a member of the team.